Study Identifies a Potential Window for Immunotherapy During Androgen Deprivation Treatment

/in /by

A new study published in the Journal for ImmunoTherapy of Cancer suggests that the timing of immunotherapy could be crucial in prostate cancer. Researchers found that androgen deprivation therapy (ADT) initially stimulates immune activity within prostate tumours, but this response gradually shifts towards immunosuppression as treatment continues. The researchers examined prostatectomy specimens from 43 patients […]

Read more

Younger Men Face Higher Mortality Risk in Advanced Prostate Cancer: An Analysis of IRONMAN Registry Data

/in /by

Younger age is generally associated with better health and longer life expectancy. However, new findings from the international IRONMAN registry suggest a different pattern in advanced prostate cancer: men diagnosed at age 55 or younger may have worse survival outcomes than those diagnosed at middle or older ages. The analysis included 4,332 patients from 15 […]

Read more

Can We Predict Deep PSA Response Before Treatment Starts? NADIR Validated in ARCHES

/in , /by

A new analysis of the phase 3 ARCHES trial suggests that a simple clinical model may help predict which men with metastatic hormone-sensitive prostate cancer are most likely to achieve a very deep PSA response after starting treatment with an androgen-receptor pathway inhibitor. The model, called NADIR, was designed to estimate the probability of reaching […]

Read more

CEA Emerges as a Potential Prognostic Marker for Lu-177 PSMA Therapy

/in /by

A simple blood test normally associated with colorectal cancer could provide additional information about how men with metastatic castration-resistant prostate cancer fare after 177Lu-PSMA-617 therapy. A new prospective study of 142 patients found that elevated carcinoembryonic antigen (CEA) before treatment was independently associated with shorter progression-free and overall survival. The finding does not mean that […]

Read more

Dietary Fat and Survival After Nonmetastatic Prostate Cancer

/in /by

A new cohort study published in JAMA Network provides some of the most detailed evidence to date on how the type of fat men eat after a prostate cancer diagnosis relates to long-term survival. The analysis, based on 4,884 participants in the Health Professionals Follow-Up Study followed for a median of 12.8 years, shows that […]

Read more

Daily Adaptive Radiotherapy After Prostate Surgery: Early Results from the DART-PHASER Study

/in /by

A new clinical study is testing a smarter way to give radiation after prostate surgery. The approach, called daily adaptive radiotherapy, uses artificial intelligence to adjust the treatment plan every day based on how the patient’s anatomy looks at that moment. Early results from the first 42 patients in the DART-PHASER trial suggest the method […]

Read more

Low 10-Year Prostate Cancer Mortality Across All Treatments: Long-Term CEASAR Data Reinforce Shared Decision-Making

/in /by

A decade after diagnosis, most men with localized prostate cancer are far more likely to die of something else than of their cancer, regardless of whether they choose surgery, radiation, or active surveillance. This is the central message of the long-term follow-up from the CEASAR study, a large, prospective, observational population-based U.S. cohort that enrolled […]

Read more

Biallelic Loss in DDR Genes and Its Clinical Impact

/in /by

Research presented during ASCO GU 2026, showed that germline DDR variants are common enough in metastatic prostate cancer to matter clinically, but their impact is highly gene-specific. In this 3,005-patient cohort, about 9% carried a germline DDR variant, and the study was especially important because it assessed both small variants and structural variants across 31 […]

Read more

A New Clue for Prostate Cancer Survival

/in , /by

A recent study, published on Nature, looked at a question that matters just as much as prostate cancer risk: why do some tumors stay quiet while others become life-threatening after diagnosis? The researchers searched for genes whose activity might be linked to survival, not just to the chance of developing the disease. To do this, […]

Read more

BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap

/in , /by

Recent real-world data clarify how homologous recombination repair (HRR) alterations, especially BRCA1/2 mutations, affect outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors (ARPIs). In a US cohort of 745 patients, overall differences in time-to-next-treatment (TTNT) and time-to-castration resistance (TTCR) were modest between patients without HRR alterations and those with non-BRCA […]

Read more